Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Moleculin Biotech, Inc. logo — Groundbreaking Cancer Therapies

Moleculin Biotech, Inc.

Groundbreaking Cancer Therapies

Founded 2006 United States Houston, United States 22 employees Post Ipo Equity Biotechnology, Pharmaceutical

General Information

Company Name Moleculin Biotech, Inc.
Founded Year 2006
Location United States Houston, United States +1
Founders / Decision Makers
Team member
Employees 22
Industries Biotechnology, Pharmaceutical
Funding Stage Post Ipo Equity
Social

Get notified when Moleculin Biotech, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. (NASDAQ: MBRX) is a clinical stage pharmaceutical company with a focus on developing a diverse portfolio of drug candidates aimed at treating highly resistant tumors and viruses. The company's lead program, Annamycin, is an innovative anthracycline designed to circumvent multidrug resistance mechanisms with minimal cardiotoxicity. It is currently being developed for the treatment of soft tissue sarcoma (STS) lung metastases and relapsed or refractory acute myeloid leukemia (AML). Moreover, Moleculin is actively involved in advancing a portfolio of antimetabolites, including WP1122, which holds potential for treating COVID-19 and other viruses, as well as various cancer indications such as brain tumors, pancreatic cancer, and others. The company is also progressing with the development of WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while triggering a natural immune response. This is targeted towards treating brain tumors, pancreatic cancer, and other cancers. Additionally, the company is working on WP1220, an analog to WP1066, intended for the topical treatment of cutaneous T-cell lymphoma. Founded in 2006, Moleculin operates within the Biotechnology and Pharmaceutical industries. The most recent milestone in the company's journey is a Post-IPO Equity investment on 16 August 2024.

Taxonomy: oncology drug development, clinical-stage pharmaceuticals, multidrug resistance mechanisms, anthracycline drug development, immunostimulating drug development, treatment of soft tissue sarcoma, treatment of acute myeloid leukemia, antimetabolite drug development, COVID-19 antiviral drug development, brain tumor treatment, pancreatic cancer treatment, cutaneous T-cell lymphoma treatment, drug development from M.D. Anderson Cancer Center discoveries, STAT3 inhibitors, tumor metabolism targeting

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 16 Aug 2024
Post-IPO Equity •••••• - 20 Dec 2023
Post-IPO Equity •••••• - 03 Feb 2021
Debt Financing •••••• - 16 May 2014
Venture - Series Unknown •••••• - 24 Apr 2013

View All 8 Funding Rounds

Moleculin Biotech, Inc. Alternatives & Competitors

Moleculin Biotech, Inc. vs
ImmunoGenesis, Inc.
ImmunoGenesis, Inc. United States

Re-envisioning cold tumor treatment. Our deliberate drug development strategy targets mechanisms of...

Series Unknown
14 employees
Biotechnology, Health Care
Moleculin Biotech, Inc. vs
Semafore Pharmaceuticals
Semafore Pharmaceuticals

Pioneering the future of cancer treatment with innovative PI3K inhibitors.

Series B
Biotechnology, Health Care
Moleculin Biotech, Inc. vs
Agensys
Agensys

Pioneering advanced treatments for cancer with innovative therapeutic antibodies and drug conjugates...

Series D
Biotechnology, Health Care

FAQ About Moleculin Biotech, Inc.

Groundbreaking Cancer Therapies
Moleculin Biotech, Inc. was founded in 2006.
Moleculin Biotech, Inc. is headquartered in Houston, United States.
Moleculin Biotech, Inc. operates in the following industries: Biotechnology, Pharmaceutical.
Moleculin Biotech, Inc. has approximately 22 employees.
Moleculin Biotech, Inc. has completed 8 funding rounds. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Moleculin Biotech, Inc. include ImmunoGenesis, Inc., Semafore Pharmaceuticals, Agensys, GeneMedicine, TME Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Moleculin Biotech, Inc. and ImmunoGenesis, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Moleculin Biotech, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes